ExonHit is a fast emerging healthcare player active in both therapeutics and diagnostics. ExonHit is based in Paris, France, and has US offices in Gaithersburg, Maryland. The Company employs 65 associates.
Navigation
President of the Management Board
Dr. Maurel has served as President of the Management Board of ExonHit Therapeutics since July 2008.
After holding various sales and marketing positions at Rhône-Poulenc and Novartis in France, he moved in 1992 to Novartis’ headquarters in Switzerland to lead global marketing for cardiovascular, metabolism and respiratory franchises. He especially orchestrated the worldwide launch of the flagship brand Diovan. In 1999, he became Novartis’ Vice President of Marketing and Specialty Business in Canada. From 2001 to 2008 he was President and CEO of Debiovision Inc., a Canadian specialty pharmaceutical company. Dr. Maurel has extensive experience in marketing, business development, licensing, clinical studies, regulatory requirements and product launches in North America, Europe and Asia. Dr. Maurel served as Chairman of the Board of Oncomab GmbH and Board member of Debiovision Inc., Avance Pharma Inc. and the BIOQuebec Association.
Dr. Maurel graduated with an M.D. from the University of Bordeaux in 1985.
He is Vice-President of the France Biotech association.